Hoffmann-la Roche Inc.

Other

Bristol-myers Squibb Compnay

F. Hoffmann-la Roche Ag

Ramakanth Sarabu

Robert Francis Kester

Nancy-Ellen Haynes

Wendy Lea Corbett

Paige Erin Mahaney

Joseph Samuel Grimsby

Fred Thomas Bizzarro

George W Holland

Joseph Francis Grippo

Jefferson Wright Tilley

Yimin Qian

Daniel Hunziker

Holger Kuehne

Hans Peter Wessel

Markus Boehringer

Steven Joseph Berthel

Nathan Robert Scott

Bernd Michael Loeffler

John A Brinkman

Jagdish Kumar Racha

Sung-Sau So

Kevin Richard Guertin

Lee Apostle McDermott

Ka Wang

Alicia Regueiro-Ren

Chinh Viet Tran

Achyutharao Sidduri

Fariborz Firooznia

Steven Gregory Mischke

Satheesh Kesavan Nair

Jacob Swidorski

Shaoqing Chen

Manoranjan Panda

Kshitij Chhabilbhai Thakkar

Brett R Beno

Adrian Wai-Hing Cheung

Hongju Li

Douglas Eric Murphy

Prasada Rao Jalagam

Frank Ruebsam

Dionisios Vourloumis

Jenny Tan

Lida Qi

Francis A Mennona

Stuart Hayden

Nicholas Marcopulos

Thomas Jay Prins

John A Brinkmann

Antonio Focella

Lee Apostle Mcdermott

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

Small molecule inhibitors of galectin-3

The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection. 

Antiviral compounds

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Inhibitors of HCV NS5A

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyridazinone glucokinase activators

The present invention provides novel compounds of formula I, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Tricyclic compounds

There are presented compounds of the formula  or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

Substituted thiazolo[5,4-d]pyrimidine urea derivatives

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

Pyrazole glucokinase activators

The present invention relates to compounds of formula (I) wherein R, R, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

DPP IV inhibitors

Pyrrolidinone glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Heteroaromatic glucokinase activators

The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

5-substituted-six-membered heteroaromatic glucokinase activators

Growing community of inventors

Towaco, NJ, United States of America

Ramakanth Sarabu